Drug index

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

Other interesting and helpful links can be found by clicking the link.

Chemotherapy safety standards

Dose adjustments

Antimicrobials

Growth factors

Approved antineoplastics

This section contains anticancer drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound. For drugs first approved within the current or prior calendar years, the date of initial approval is also provided here.

A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

Q

R

S

T

U

V

Z

Discontinued antineoplastics

This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.

A

D

E

F

L

M

O

P

S

T

U

V

Investigational antineoplastics

This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.

A

B

C

D

E

F

G

H

I

J

L

M

N

O

P

Q

R

S

T

U

V

Z

Supportive and other medications

This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.

A

B

C

D

E

F

G

H

I

L

M

N

O

P

Q

R

S

T

U

V

W

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Drugs in a REMS program

Cytotoxic Chemotherapy

Kinase inhibitors

Endocrine therapy

Investigational and Discontinued

Biologics

Supportive Medications

Radioactive agents

Benign Hematology Medications

Hematopoietic Growth Factors

Miscellaneous

Medications by Condition

Medications by Route of Administration

Medications by Year of Approval

Interesting and Helpful Links

References

  1. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  2. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=84824"